🏛️ Verified NIH Record • Updated 2025-11-04
Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial (NCT03173976)
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Mohammed Milhem
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this single arm open label phase 1b clinical study is to see what effect zoledronic acid has on tumors in patients with resectable any grade chondrosarcoma prior to surgery.
Who can join: Review the eligibility criteria below.
Location: University of Iowa Hospitals and Clinics — Iowa City, Iowa
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University of Iowa Hospitals and Clinics — Iowa City, Iowa
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chondrosarcoma
- AG-120 in People With IDH1 Mutant Chondrosarcoma — Baltimore, Maryland
- Proton Beam Therapy for Chondrosarcoma — Houston, Texas
- Understanding Engagement Trends in Chondrosarcoma Clinical Trials — San Francisco, California
- Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration — Jacksonville, Florida
Explore by condition: All Chondrosarcoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.